The International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation (LCRF) are now accepting proposals for the IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers. This competitive opportunity will provide up to $2.5 million in funding during a 4-year period for research teams focused on curing oncogene-driven lung cancers.
Research teams with closely integrated projects that would not otherwise be realized by a single component from the team are encouraged to submit a letter of intent by March 4, 2024, and their full proposal by August 1, 2024.
Work supported through this team science award will address important mechanistic questions and develop therapeutics across the care continuum, with the immediate potential to increase survivorship. A clinical trial must either be initially incorporated into the project or be an immediate result of the outcome of the research.
“Resistance in oncogene-driven lung cancers is a frustrating inevitability for these patients,” said LCRF Chief Scientific Officer Antoinette Wozniak, MD. “Partnering with IASLC on funding research that will bring us closer to a cure is not only exciting; it is the right thing to do.”
Complete details, including eligibility criteria and application instructions, can be found on the LCRF website.
